Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Their were dozens & dozens of companies working on vaccines for CV-19 that went up thousands of percentage points. I hit NVAX from under $10.00-high $200 hundreds. A handful working on fast acting low side effect depression & anxiety meds. between a third to half the population are dealing with depression & anxiety this is a HUGE un tapped market for second generation Depression & anxiety meds. First generations work about 30% of the time take months to kick into the blood stream and have massive side effects Thats where VTGN comes into play Boomage!!!!!!! massive roi from these levels. Jeffries just put out a $6-8 target this year for VTGN Multi billion market in the making..
VTGN is the only company that I'm aware of working on fast acting 15 min or less with very low side effects Second generation Depression & anxiety meds.
Phase 3 Ready
Multiple Phase 2's
World renown psychologists Michael Liebowitz heading VTGN trials is this very valuable resource to VTGN
https://ir.vistagen.com/press-releases/detail/98/vistagen-therapeutics-appoints-dr-michael-liebowitz-to-cns He developed the
Liebowitz scale he is heading all our trials for VTGN
https://nationalsocialanxietycenter.com/liebowitz-sa-scale/
including VistaGen PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
VTGN Institutional Shares have skyrocketed to 61% this year.From 7% last year
Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics.
https://www.reuters.com/article/us-biogen-sage/biogen-bets-on-depression-drug-in-1-5-billion-deal-with-sage-therapeutics-idUSKBN2871GU
From what i understand this company is being looked at by multiple big pharma companies in regards to being bought out Sage was just bought out VTGN has 14 indications in their pipeline for depression & anxiety meds.
VTGN pipeline
https://www.vistagen.com/pipeline
VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf
VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Anxiety depression peers:
$CMPS 2 billion market cap early clinical trials. 190 million cash
$MMEDF 1.2 billion market cap.
$SAGE 3 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 333 million market cap Phase 3 ready. (nasdaq)
115 million in cash
$VTGN
SOFTBANK IS SAID TO PLAN BILLIONS TO INVEST IN BIOTECH STOCKS interest in CNS markets highlighting depression drugs.....
WEAK HANDS shake shake shake shake , while smart money is BUYING BUYING BUYING!!
VTGN50 million shares traded in days from $2.00=$3.18
VTGN 15 million shares traded last 2 days from 3.18-2.05
$VTGN
WEAK HANDS shake shake shake shake , while smart money is BUYING BUYING BUYING
$PDSB
1 in 3 adults are depressed or anxious due to COVID-19
https://www.weforum.org/agenda/2021/02/covid19-mental-health-depression-anxiety/
Anxiety, Depression and Drinking During a Pandemic
https://www.webmd.com/lung/news/20210125/anxiety-depression-and-drinking-during-a-pandemic
Coronavirus Survey: One-Third of U.S. Adults Have Symptoms of Depression or Anxiety
https://www.usnews.com/news/healthiest-communities/articles/2020-05-27/one-third-of-us-adults-have-signs-of-depression-anxiety-during-pandemic
Suicides Increasing Following FDA’s Boxed Warning Implementation on Antidepressants
https://www.hcplive.com/view/suicides-fda-boxed-warning-antidepressants
lots of demand for next generation anxiety and depression meds low side effects and fast acting multi billion dollar market cap. I'm adding up to $2.60 My average price is still under a $1.00 $10.00 stock target this year.
VTGN Pipeline:
https://www.vistagen.com/pipeline
VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf
VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Anxiety depression peers:
$CMPS 2 billion market cap early clinical trials. 190 million cash
$MMEDF 1.2 billion market cap.
$SAGE 3 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 357 million market cap Phase 3 ready. (nasdaq)
115 million in cash
Depression and anxiety one of the most sought after sector in biotech large population of people in the world are depressed.
93% increase in people participating in anxiety screenings, according to Mental Health America.
Study finds Colorado has 31% average rate of depression and anxiety.
https://www.denverpost.com/2021/02/18/mental-health-colorado-pandemic-anxiety-depression/
I invested in MVIS mid 2.00's and saw it run into the mid 20.00's in 3 months time 12 weeks ago similar share structure as VTGN I believe VTGN could head into the $20.00 range sooner than later.
Nasdaq going down due to some overvalued tech stocks rotation into small cap biotechs is where the smart money is going. Hint Hint
I always buy when there is panic in the markets thats why I do really well.
$VTGN
some of riots management has had some checkered past and has dealt with the SEC on multiple violations in the past. I saw the CEO talk on CNBC the other day didn't seem that impressive to me.
$MARA
Added another 5k the only thing I see stopping this stock short term is another offering they have less than 30 million in the bank. It might be better for them to get it out of the away now. Either way you need to have diamond hands. Thanks MM for the cheapies you clowns. Hold the line probably going to try and push this under $5.00 again
$PDSB
VTGN Dec 2020's $100M public offering, 5-8 year price target of $101.00
https://seekingalpha.com/article/4400577-vistagen-patience-lead-to-significant-upside
VTGN Pipeline
https://www.vistagen.com/pipeline
VTGN website:
https://www.vistagen.com/
VTGN 2021 Biz Presentation
https://d1io3yog0oux5.cloudfront.net/_56bf463cab7dbe03c2fae6d0fc89eeed/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+Version+2021_02_02.pdf
Anxiety depression peers:
$CMPS 2 billion market cap early clinical trials. 190 million cash
$MMEDF 1.2 billion market cap. low cash reserves phase 2's
$SAGE 3 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 357 million market cap Phase 3 ready.115 million in cash
$VTGN
Agreed added the dip here. This is the King of all Miners. Mara is the one to own even over Riot.
$MARA
Yellen is going to help catapult Bitcoin into the six figures and GBTC into the triple digits.
$GBTC
If it dips again after this update I will add more.
$PDSB
VTGN Institutional Shares have skyrocketed to 61% this year.From 7% last year.
Cash runway into 2023
$VTGN
What a beast!
$BEAM
VTGN has all the boxes checked off. 115 million plus cash in the bank.
Deep pipeline next generation depression and anxiety meds.
VTGN fast acting 15 min & low side effects.
First generation depression meds have a 30% success rate at best very high side effects & takes months to start to take effect.
VTGN Phase 3 ready Fast tracked. Social Anxiety Disorder
Multiple phase 2's including VistaGen PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)
VTGN Institutional Shares have skyrocketed to 61% this year.From 7% last year
Added up today bought a stash at 2.53 right before close Company hit a new 52 week high today.
VTGN multi billion dollar depression/anxiety pipeline Be Patient & add at these levels. If Mindmed is valued at 1 Billion market capitalization roughly 30 million in cash nearing phase 2B is MMEDF furthest drug out in trials.
VTGN 115 million in cash market cap 360 million Phase 3 Ready Anxiety low side effects fast acting and a phase 2 Covid fast tracked indication for depression starting early 2021 both. fast tracked. This stock probably be 20.00+ 2021-2022 Buy and hold. multi Billion dollar market cap in the making.
next generation depression and anxiety drugs is a smart place to be invested for massive ROI.
World renown psychologists Michael Liebowitz heading VTGN trials is this very valuable resource to VTGN
https://ir.vistagen.com/press-releases/detail/98/vistagen-therapeutics-appoints-dr-michael-liebowitz-to-cns He developed the
Liebowitz scale he is heading all our trials for VTGN
https://nationalsocialanxietycenter.com/liebowitz-sa-scale/
Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics
https://www.reuters.com/article/us-biogen-sage/biogen-bets-on-depression-drug-in-1-5-billion-deal-with-sage-therapeutics-idUSKBN2871GU
COVID-19 disrupting mental health services in most countries, WHO survey World Mental Health Day to highlight urgent need to increase investment in chronically underfunded sector..
The COVID-19 pandemic has disrupted or halted critical mental health services in 93% of countries worldwide while the demand for mental health is increasing, according to a new WHO survey. The survey of 130 countries provides the first global data showing the devastating impact of COVID-19 on access to mental health services and underscores the urgent need for increased funding.
https://www.who.int/news/item/05-10-2020-covid-19-disrupting-mental-health-services-in-most-countries-who-survey
VTGN Pipeline:
https://www.vistagen.com/pipeline
VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf
VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
Anxiety depression peers:
$CMPS 2 billion market cap early clinical trials. 190 million cash
$MMEDF 1.2 billion market cap.
$SAGE 3 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 357 million market cap Phase 3 ready. (nasdaq)
115 million in cash
Depression and anxiety one of the most sought after sector in biotech large population of people in the world are depressed.
93% increase in people participating in anxiety screenings, according to Mental Health America.
Study finds Colorado has 31% average rate of depression and anxiety.
https://www.denverpost.com/2021/02/18/mental-health-colorado-pandemic-anxiety-depression/
I invested in MVIS mid 2.00's and saw it run into the mid 20.00's in 3 months time 12 weeks ago similar share structure as VTGN I believe VTGN could head into the $20.00 range sooner than later. Volume pattern looks very similar to MVIS before it surged into the double digits.
$VTGN
sure does!
$PDSB
Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
Boomage
stick a fork in it shorties.
$PDSB
You might want to contact PDSB PR
info@pdsbiotech.com
$PDSB
This sucks guess where not holding the line!
$PDSB
PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune®-Based T-Cell Inducing COVID-19 Vaccine
Brazilian-based Blanver brings depth of expertise in development and commercialization of innovative pharmaceuticals across Latin America
https://www.globenewswire.com/news-release/2021/02/22/2179586/0/en/PDS-Biotech-and-Farmacore-Announce-Blanver-to-Join-Consortium-to-Commercialize-Novel-Versamune-Based-T-Cell-Inducing-COVID-19-Vaccine.html
$PDSB
Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
Let's all hold the Line here at show these market makers who's boss.
$PDSB
added to the stash closing in on 100k shares!
$PDSB
These market makers are straight clowns super low brow buffoons.
They just flashed a 1
1. 100 - I need Shares.
Let's show these punks whats up. News is about to drop watch!!!!
911 - Pending News/Press Release On The Way LOL
https://valemaisrs.com.br/noticia_ver.php?news=3333
GRTS went from a few dollars to $35.00 in a blink of an eye on second generation CV-19 vaccine. These MM are going to need to stay away from high rise buildings MM are toast I eat fools like this for breakfast!!!
Put your shares GTC sky high this stock is moving Like NVAX when I was buying it under $10.00 PDSB technology is a quantum leap ahead of NVAX Vaccine Technology they don't even have cancer indications.
$PDSB
Second generation CV-19 Vaccine. PDS0203 (SARS-CoV-2)
The results obtained so far demonstrate that the vaccine induces the generation of neutralizing antibodies and, at the same time, reinforces the immune response by activating the cellular defense system. The expectation is that this combination - the generation of antibodies against protein S and activation of T cells - will provoke a robust immune response and offer a long-term immunization, capable of facing the virus mutations.
Hold the Line add to your stash we will make up one morning up hundreds of percentage points from these levels. Let's smack the market makers across the face. Don't sell your shares and let them rob you and buy them back when these criminals launch the price we will retest 7.30 and break into double digits. Put your shares GTC sky high. The whole float was traded at higher prices they are taking your hard earned money and have lowered the price on very low volume MM market makers are the scum of the earth.
PDSB has the second generation vaccine to fight variants.
Second generation CV-19 to treat variant strains & universal flu plus oncology pipeline 3 drugs in phase 2.
PDSB no debt cash runway into mid 2022 small float large insider & institutional holders.
Normalcy will return only with second generation of Covid-19 vaccine: Bill Gates
PDSB has partnered with some of the world’s leading research institutions and pharmaceutical companies to develop more effective Versamune®-based cancer therapies and infectious disease second generation vaccines to save lives.
PDSB biz presentation 2021
https://www.pdsbiotech.com/images/pdf/presentation/2021/PDSB_Corporate_Overview_-_Jan_2021_FINAL-1.pdf
PDSB website:
https://www.pdsbiotech.com/
$PDSB
PDS Biotechnology (PDSB) C-Suite Interview with CEO Frank Bedu-Addo
$PDSB Updates that could come any day:
**PDS0201 -Tuberculosis - literally no mention of this since early last year.
**PDS0202 - Universal flu vaccine - NIAID grant awarded back in July for accelerated development. No word since then but you'd think they'd have some type of pre-clinical data at this point (Univ. of Kentucky is collaborator)
**PDS0203 - covid second generation vaccine - various articles indicate human trials starting in May in Brazil - no updates from company on funding by gov. or confirmation of trial timeline. EOY Ready through accelerated program in Brazil.
PDS0101 - (triple combo) - preliminary efficacy and safety data on additional 5 patients in 1st cohort. Interim data in Q2/Q3 per presentation. Additionally, "Confirmation that PDS0101 enhances the therapeutic benefit of M7824 & NHS IL-12 may lead to
expanded evaluation in several cancers with PDS0102-0104
Wild card: Funding news/partnerships for anything within their pipeline - eyes on PDS0104
PDSB Feb 2021 Biz presentation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/PDSB_Corporate_Overview_-_Feb_2021_FINAL.pdf
PDSB Website:
https://www.pdsbiotech.com/
$PDSB
I'm going to add tomorrow as well.
We could see $7.30+ here soon.
Lock up your shares.
Give them nothing.
Take from them everything.
We ride this to double digit dollars.
Catalysts & new analysts updates coming.
$PDSB
Great Find.
VERSAMUNE®
PLATFORM
Our Versamune® platform trains the immune system to unleash a powerful targeted T-cell attack and could dramatically improve treatment and patient outcomes across the cancer spectrum & infectious diseases.
The development of more effective vaccines is critical in the fight against pathogens that cause certain diseases including tuberculosis, influenza and coronaviruses. Vaccines that induce virus-specific killer T-cell responses in addition to neutralizing antibodies are much more effective in providing protection against severe illness caused by such viruses. An ideal vaccine.
Stimulate the immune system to recognize the pathogen and induce potent antibody response for near-term protection.
Induce potent killer T-cell and memory T-cell response for long-term protection.
Provide protection safely with no clinically relevant toxicities.
A.Induction of high levels of active
CD8+ (killer) T-cells.
B.Induction of high levels of CD4+
(helper) T-cells.
C.Ability to overcome tumor immune
suppression.
D.Induction of long-term memory CD8+
T-cells.
$PDSB
Set those limit sales high to prevent shorting with your shares...
I love clowning these Buffoon MM I'm in close contact with the company and everything is moving forward. I believe our Universal Flu & CV-19 vaccine are multi billion dollar markets. Remember Brazil plans on having our CV-19 Vaccine ready for market by the end of this year. Brazil has 211 million people PDSB Cancer indications are also multi billion dollar markets.
We will be moving up soon you can make book on that.
Feb 9 1.5 million shares traded
Feb 10 6.9 million shares traded
Feb 11 8.7 million shares traded
22 million shares outstanding
28% held by insiders.
15% held by institutions.
$PDSB
We are golden investors should know what they own. Could see a pop like IMNM on variant CV strain protection PDSB has the T cell technology to protect against variant strains.
3 Phase 2 Cancer trials with top cancer organizations Mc Anderson NIH & MERCK.
Development of PDS0203 - A second generation COVID-19 vaccine that
promotes powerful T-cell responses and neutralizing antibodies
clinical studies show powerful induction of long-lasting polyfunctional CD8+ and
CD4+ anti-SARS-CoV-2 T-cells
PDSB Feb 2021 Biz presentation.
https://www.pdsbiotech.com/images/pdf/presentation/2021/PDSB_Corporate_Overview_-_Feb_2021_FINAL.pdf
PDSB Website:
https://www.pdsbiotech.com/
$PDSB
Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee.
Every time in the history of Bitcoin it has 10x after breaking a new high 200K bitcoin is coming. Then 2 million after the 200k gets broken. Never sell your BTC lock and key it forever.
Bitcoin is the highest appreciating asset in history of civilization and it's just getting started.
The Long And Winding Road To A $10 Million Bitcoin
https://medium.com/@lucidfunds/the-long-and-winding-road-to-10-million-bitcoin-4b1c83d26e5d
Tesla and Elon Musk Buy Bitcoin — This is End Game Now. |
https://medium.com/yardcouch-com/tesla-and-elon-musk-buy-bitcoin-this-is-end-game-now-daf103a73181
MicroStrategy Ups Note Offering For Buying More Bitcoin To $900 Million
https://bitcoinmagazine.com/articles/microstrategy-ups-raise-target-for-buying-more-bitcoin-to-900-million
Twitter CEO Jack Dorsey has been buying $10,000 worth of Bitcoin per week.
https://finance.yahoo.com/news/twitter-ceo-jack-dorsey-buying-140005439.html
Square, Inc. Invests $50 Million in Bitcoin
https://squareup.com/us/en/press/2020-bitcoin-investment
The Motley Fool Announces $5 Million Investment in Bitcoin
https://www.fool.com/investing/2021/02/17/the-motley-fool-announces-5-million-investment-in/
MarketWatch: Bitcoin could hit $250,000 if companies opt to do this, says Cathie Wood.
https://www.marketwatch.com/story/bitcoin-could-hit-250-000-if-u-s-companies-opt-to-do-this-says-cathie-wood-11613593981
Tesla’s next business: Turning your solar roof and EV into Bitcoin mines.
Your roof or your next car could become the ultimate idle cash generator game.
https://www.zdnet.com/article/teslas-next-business-turning-your-solar-roof-and-evs-into-bitcoin-mines/
If Bitcoin climbs to $10 million per Bitcoin, it could provide the world community with a stable currency, replace sovereign currencies, and act as the reserve currency of the world incapable of inflation or deflation. It would represent the ultimate “Store of Value”.
As of June 2020, roughly 18.6 million Bitcoin has been mined. We break that 18.6 million Bitcoin down into three buckets based on its movements to date:
Roughly 60% of that Bitcoin is held by entities — either people or businesses — that have never sold more than 25% of Bitcoin they’ve ever received, and have often held on to that Bitcoin for many years, which we label as Bitcoin held for long-term investment.
Another 20% hasn’t moved from its current set of addresses in five years or longer. We consider this lost Bitcoin.
That leaves just 3.5 million Bitcoin — or 19% of all mined Bitcoin — that moves frequently, primarily between exchanges, which we label as Bitcoin used for trading.
HODL
$GBTC
SURF they have 6 very promising antibody molecules.
GSK puts up to $815M on the table for Surface Oncology's antibody.
https://www.fiercebiotech.com/biotech/gsk-puts-up-to-815m-table-for-surface-oncology-s-antibody
Surface Oncology (SURF) Explores Potential Sale After GSK Takeover Approach - Source
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html
Cathie Wood from ARKG has been buying SURF everyday a million share purchase in one day a few weeks back.
2021/2/16
ARKG 3,883,960 (+35,028)
9.55% of outstanding shares.
Novartis 9.71% holding.
Eli Lily holds 8.5% through LLV ventures fund.
Cash runway into 2023
Licensing agreements with $NVS $GSK and $MRK??
SRF617 (100% OWNED) - Targets CD39
SRF388 (100% OWNED) - Targets IL27
SRF813 (GSK 830M DEAL) - Targets PVRIG
NZV930 (Deal with Novartis)
SRF114 Targets CCR8
Cup and handle forming on the weekly!
Take a look at this chart get in before the pop to $15-$20
https://stockcharts.com/h-sc/ui?s=surf
$SURF
$SURF they have 6 very promising antibody molecules.
2021/2/16
ARKG 3,883,960 (+35,028)
9.55% of outstanding shares.
Eli Lily holds 8.5% through LLV ventures fund.
$SURF
2021/2/16
ARKG 3,883,960 (+35,028)
9.55% of outstanding shares
$SURF
There is a RAF Fire trigger on the 30 min this is very close to bottoming out and on its way to new 52 week highs.
Cup and Handle forming on the weekly.
Catch a wave.
$SURF
Need the weak hands to be rinsed then we will go up.
I have all the patience in the world. I'm in $2.45
$PDSB
Cathie Wood from ARKG owns 10% and keeps adding shares. of the SURF float.
Eli Lily holds 8.5% through LLV ventures fund.
Novartis owns 10% institutions own 67% of the 40 million shares outstanding.
institutions own 68% of the 40 million shares outstanding.
Potential of 1.2 Billion in total payments from Novartis & GSK with double digit royalties. Also partnered with Merck.
https://www.fiercebiotech.com/biotech/gsk-puts-up-to-815m-table-for-surface-oncology-s-antibody
Surface Oncology (SURF) Explores Potential Sale After GSK Takeover Approach - Source
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html
Jim Cramer Surface Oncology Is Set for Further Gains.
https://realmoney.thestreet.com/investing/surface-oncology-is-set-for-further-gains-how-to-buy-it-15542979
http://www.surfaceoncology.com
Golden Chart!
https://stockcharts.com/
$SURF
SEC Form SC 13G/A filed
https://quantisnow.com/insight/399449?s=s
Follow the bread crumbs!
Added to my stash!!
Surface Oncology (SURF) Explores Potential Sale After GSK Takeover Approach - Source
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html
Charts Golden
https://stockcharts.com/h-sc/ui?s=SURF
Cathie Wood of ARKG keeps buying SURF wonder why? million share buy a few weeks back.And she keeps increasing her SURF position day after day!
$SURF
Cathie Wood from ARKG literally bought a cool million SURF shares in one day a few weeks ago. She has the best financial research team & tools and is in close contact with SURF management. ARKG Cathie Wood now owns close to 10% of the shares and she has been Buying SURF shares almost every day.
Surface Oncology hires bankers to explore sale - StreetInsider
The company received a takeover approach from GlaxoSmithKline (GSK)
and has hired an investment bank, StreetInsider reports.
Surface Oncology wants bankers to look for any other possible M&A interest beyond GSK, StreetInsider says.
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html
FDA Fast tracks SRF388 (Surface Oncology), a fully human anti-interleukin-27 antibody, for treatment of patients with hepatocellular carcinoma
Cathie Wood from ARKG owns 10% and keeps adding shares. of the SURF float Eli Lily holds 8.5% through LLV ventures fund. Novartis just disclosed a roughly 10% stake after hours via Form SC 13G. institutions own 67% of the 40 million shares outstanding
Cash runway through 2023 ($102.5M in cash as of Sept 30th; received $85Million from GSK GlaxoSmithKline in December.
Two strategic partnerships (Novartis & GSK GlaxoSmithKline) validate strong IO drug discovery capabilities.
GSK GlaxoSmithKline Partnership SRF813
cumulative milestones up to $730 million
• Tiered royalties on annual net sales
(high single-digit to mid-teens %
Novartis Partnership: NZV930
• Upfront payment of $70M, total
cumulative milestones up to $525 million
• Tiered royalties on annual net sales
(high single-digit to mid-teens %)
Detailed clinical update for both SRF617 & SRF388 to be presented in the first half of 2021.
SRF388 is the ONLY anti IL-27 targeted agent in clinical development. Shows antimetastatic tumour activity and increased the production of key inflammatory cytokines.
SRF388 is a blockbuster in the making, the Il-27 targeting antibody. There is compelling evidence clinically to understand IL-27s role in tumour types. This is the next one that will get huge partnership deal!!
Total = $1.2B Billion just for licence worldwide rights with Novartis & GSK plus double digit tiered royalties.
Surface Oncology Announces FDA Fast Track Designation Granted by U.S. Food and Drug Administration for SRF388 to Treat Liver Cancer.
https://investors.surfaceoncology.com/news-releases/news-release-details/surface-oncology-announces-fda-fast-track-designation-granted-us
SURF has 4 other VERY promising targets. SRF617,SRF388, SRF114,SRF231 More partnership deals to come.
undervalued and the chart is bullish 1 year is amazing building & looking for continuation to the upside.
SURF Chart cup and handle on the weekly!!
https://stockcharts.com/h-sc/ui?s=SURF
Outstanding team of experienced company builders & oncology drug developers.
In the "Lightning Round" segment of Mad Money Friday night, Jim Cramer was bullish on Surface Oncology (SURF) , an immuno-onocolgy company developing next-generation antibody therapies.
https://realmoney.thestreet.com/investing/surface-oncology-is-set-for-further-gains-how-to-buy-it-15542979
SURF Feb 2021 Biz presentation:
https://investors.surfaceoncology.com/static-files/9a6d888d-dae2-419d-a0fc-c96058f9aa7c
Surf Website:
https://www.surfaceoncology.com/
Surf Pipeline & Programs:
https://www.surfaceoncology.com/pipeline-programs/
$SURF
Huge cup and handle forming on the weekly.
Continue uptrend. New highs in the forecast.
MACD turning up here along with RSI would be very bullish.
https://stockcharts.com/h-sc/ui?s=SURF
Cathie Wood from ARKG has been buying SURF aggressively and doubled her position in 2021 4 million shares. She liked TSLA at $30.00 Bitcoin at $500 Cathie Knows.
Novartis owns 10% of the total shares.
Eli Lily holds 8.5% through LLV ventures fund.
institutions own 67% of the 40 million shares outstanding
$SURF
SURF Oncology Chart speaks for itself.
https://stockcharts.com/h-sc/ui?s=SURF
About Surface Oncology®
SURF team is on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families.
Cathie Wood ARKG owns 10% of the total shares.
Novartis owns 10% of the total shares.
Eli Lily holds 8.5% through LLV ventures fund.
institutions own 67% of the 40 million shares outstanding
Potential of 1.2 Billion in total payments from Novartis & GSK with double digit royalties. Also partnered with Merck.
https://www.fiercebiotech.com/biotech/gsk-puts-up-to-815m-table-for-surface-oncology-s-antibody
Surface Oncology (SURF) Explores Potential Sale After GSK Takeover Approach - Source
https://www.streetinsider.com/Hot+M+and+A/Surface+Oncology+%28SURF%29+Explores+Potential+Sale+After+GSK+Takeover+Approach+-+Source/17458243.html
http://www.surfaceoncology.com
$SURF